Insider Selling: Insmed (NASDAQ:INSM) CEO Sells 13,396 Shares of Stock

Insmed, Inc. (NASDAQ:INSM) CEO William Lewis sold 13,396 shares of Insmed stock in a transaction on Monday, February 9th. The shares were sold at an average price of $147.79, for a total transaction of $1,979,794.84. Following the transaction, the chief executive officer owned 301,185 shares in the company, valued at approximately $44,512,131.15. This trade represents a 4.26% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

William Lewis also recently made the following trade(s):

• On Tuesday, February 3rd, William Lewis sold 3,009 shares of Insmed stock. The stock was sold at an average price of $156.34, for a total value of $470,427.06.
• On Tuesday, January 20th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $158.93, for a total transaction of $1,700,392.07.
• On Monday, January 12th, William Lewis sold 19,215 shares of Insmed stock. The stock was sold at an average price of $169.00, for a total transaction of $3,247,335.00.
• On Thursday, January 8th, William Lewis sold 3,223 shares of Insmed stock. The shares were sold at an average price of $174.17, for a total value of $561,349.91.
• On Wednesday, January 7th, William Lewis sold 2,357 shares of Insmed stock. The stock was sold at an average price of $175.07, for a total transaction of $412,639.99.
• On Tuesday, January 6th, William Lewis sold 4,096 shares of Insmed stock. The shares were sold at an average price of $173.33, for a total value of $709,959.68.
• On Thursday, December 18th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $166.97, for a total value of $1,786,412.03.

Insmed Stock Down 0.1%

Insmed stock traded down $0.12 during trading hours on Wednesday, reaching $148.43. The stock had a trading volume of 1,495,878 shares, compared to its average volume of 2,535,789. Insmed, Inc. has a 52 week low of $60.40 and a 52 week high of $212.75. The business’s 50 day moving average price is $172.50 and its 200-day moving average price is $161.37. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.63 and a quick ratio of 4.34. The company has a market cap of $31.66 billion, a price-to-earnings ratio of -23.98 and a beta of 1.11.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. CIBC Private Wealth Group LLC boosted its stake in shares of Insmed by 42.1% during the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 53 shares during the last quarter. Kingsview Wealth Management LLC increased its position in Insmed by 2.7% during the 3rd quarter. Kingsview Wealth Management LLC now owns 2,321 shares of the biopharmaceutical company’s stock worth $334,000 after purchasing an additional 60 shares in the last quarter. Choreo LLC increased its position in shares of Insmed by 2.9% in the third quarter. Choreo LLC now owns 2,319 shares of the biopharmaceutical company’s stock worth $334,000 after acquiring an additional 65 shares in the last quarter. EverSource Wealth Advisors LLC raised its position in Insmed by 10.2% in the fourth quarter. EverSource Wealth Advisors LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $130,000 after purchasing an additional 69 shares during the period. Finally, ORG Partners LLC raised its holdings in shares of Insmed by 12.7% during the 4th quarter. ORG Partners LLC now owns 657 shares of the biopharmaceutical company’s stock valued at $114,000 after buying an additional 74 shares during the period.

Wall Street Analyst Weigh In

INSM has been the subject of a number of analyst reports. Wolfe Research set a $167.00 price target on Insmed and gave the company an “outperform” rating in a research report on Thursday, December 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Insmed in a report on Thursday, January 22nd. UBS Group lowered their target price on Insmed from $223.00 to $215.00 and set a “buy” rating for the company in a report on Tuesday, January 6th. Cantor Fitzgerald boosted their price target on shares of Insmed from $216.00 to $230.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 16th. Finally, Jefferies Financial Group set a $269.00 target price on shares of Insmed in a research note on Wednesday, December 10th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $204.24.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.